DJO Global said last Friday it notified certain customers to a possible breach of personal information after a set of patient product agreement forms were lost in transit.
The San Diego, Calif.-based company said that it discovered the possible breach on September 25, 2017 which involved the “potential disclosure of certain personal information of individuals” who received products from the Las Vegas-based St. Rose Dominican Hospital’s Siena, San Marin or De Lima campuses between July 17, 2017 and October 16, 2017.
The breach affects patients who were treated at the hospital in the emergency room, same day surgery center or urgent care sites who may have filled out a DJO Global patient product agreement form, as the forms were lost in transit some time before being picked up and dropped off at a FedEx location.
“To the best of DJO’s knowledge, the forms were likely lost in transit between the time (1) DJO’s vendor picked up the form from St. Rose Dominican Hospital, and (2) dropped the forms off at FedEx,” the company said in a press release.
DJO Global said it notified impacted individuals to the best of its ability, and that lost information includes names, addresses, phone numbers, date of birth, physician details, product, injury and device details and health plan information which could include social security numbers.
The company said that so far, there’s no evidence that the information has been misused, but instructed impacted individuals to place a 90-day fraud alert on their credit file and to take steps to protect from any misuse. DJO Global said it would also provide complimentary credit monitoring services to potentially affected individuals.
“DJO is taking this matter very seriously and has conducted a thorough investigation to mitigate the circumstances resulting from this incident. To ensure an incident like this does not happen again, DJO has implemented new quality controls in its mailing processes and retrained its vendor on the safeguarding of paper records containing protected health information,” the company wrote in a press release.
Last June, DJO Global said it plans to launch a clinical trial for a new indication of the company’s bone growth stimulator.
